HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Intermittent versus continuous pantoprazole infusion in peptic ulcer bleeding: a prospective randomized study.

AbstractBACKGROUND AND AIM:
Rebleeding has remained the most important determinant of poor prognosis in peptic ulcer bleeding. Gastric acid plays an important role in the pathogenesis of rebleeding. We aimed to compare the efficiency of intermittent and continuous pantoprazole infusion treatment on peptic ulcer rebleeding after endoscopic therapy.
MATERIALS AND METHOD:
In this prospective study, patients with active peptic ulcer bleeding or non-bleeding visible vessel were treated initially with endoscopic therapy. They were randomized to receive intermittent or continuous intravenous pantoprazole treatment. Rebleeding rate, duration of hospital stay, need for total blood transfusion and need for urgent surgery were compared among both groups.
RESULTS:
Rebleeding rate (6.1 vs. 8.3%), duration of hospital stay (4.17 vs. 4.41), need for total blood transfusion (2.18 vs. 2.59) and need for urgent surgery (4.1 vs. 4.2%) were similar in intermittent and continuous pantoprazole infusion therapy groups, respectively. There was no bleeding-related death in either group.
CONCLUSION:
In patients with peptic ulcer bleeding, intermittent and continuous pantoprazole infusion after successful endoscopic therapy have comparable outcomes in reducing rebleeding. Both have similar effects on hospital stay, need for blood transfusion and urgent surgery. Intermittent administration has application and cost advantages over continuous infusion.
AuthorsIlhami Yüksel, Hilmi Ataseven, Seyfettin Köklü, Ibrahim Ertuğrul, Omer Başar, Bülent Odemiş, Mehmet Ibiş, Nurgül Saşmaz, Burhan Sahin
JournalDigestion (Digestion) Vol. 78 Issue 1 Pg. 39-43 ( 2008) ISSN: 1421-9867 [Electronic] Switzerland
PMID18824852 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
Copyright2008 S. Karger AG, Basel.
Chemical References
  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Ulcer Agents
  • Pantoprazole
Topics
  • 2-Pyridinylmethylsulfinylbenzimidazoles (administration & dosage)
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Ulcer Agents (administration & dosage)
  • Duodenal Ulcer (drug therapy)
  • Endoscopy, Gastrointestinal
  • Erythrocyte Transfusion
  • Female
  • Humans
  • Infusions, Intravenous
  • Length of Stay
  • Male
  • Middle Aged
  • Pantoprazole
  • Peptic Ulcer Hemorrhage (drug therapy)
  • Prospective Studies
  • Recurrence
  • Stomach Ulcer (drug therapy)
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: